PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.\', \'Department of Experimental and Clinical Medicine, \'Magna Graecia\', University of Catanzaro, Catanzaro, Italy.\', \'Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russian Federation.\', \'Complejo Hospitalario de Navarra, IDISNA, Pamplona, Spain.\', \'Hospital Universitario de Galdakao, Galdakano, Spain.\', \'Hospital Universitario de Araba - sede Txagorritxu, Vitoria, Spain.\', \'Hospital Universitario de Donostia, San Sebastian, Spain.\', \'Hospital Universitario de Cruces, Bilbao, Spain.\', \'Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain. emartinsan@unav.es.\', \'Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain. bpaiva@unav.es.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41408-021-00594-1
?:hasPublicationType
?:journal
  • Blood cancer journal
is ?:pmid of
?:pmid
?:pmid
  • 34907159
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.727
?:rankingScore_hIndex
  • 30
is ?:relation_isRelatedTo_publication of
?:title
  • Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34907159>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34907159>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all